AI enabled Acceleration of Preclinical Biologic Drug Development

Great Bay Bio (“GBB”) proposes a Belt & Road AI Preclinical Acceleration Platform to help pharma sponsors, research institutions and investors turn promising ideas into stronger biologic opportunities.

Many emerging life-sciences markets possess disease insight, research talent, early targets and biologic assets, but lack an integrated path from discovery to a developable preclinical candidate. Molecular design, laboratory validation, developability assessment, cell-line development, early CMC planning and partnering are often fragmented. This can slow investment decisions, weaken locally originated assets and limit participation in higher-value biopharma activities.

GBB proposes a shared, country-led platform that gives qualified partners access to AI-enabled biologics design and optimisation, wet-lab validation, early developability assessment and CMC-oriented development. The objective is not to guarantee a clinical outcome. It is to generate stronger data and earlier decision points, allowing sponsors and investors to make more disciplined go, no-go, co-development and partnering decisions.

GBB’s owns an AI-native platform connecting proprietary data, AI models, biologics engineering, wet-lab validation, cell-line development, media optimisation and CMC preparation in a dry-wet feedback loop. This integration matters because a promising sequence may still fail on affinity, humanisation, stability, expression, aggregation, manufacturability or scale-up. GBB’s proposed contribution is to bring these development considerations forward into preclinical work.

The initiative would begin with one or two anchor-market pilots. An anchor investor, strategic institution or local pharmaceutical partner would define priorities, nominate qualified programs and establish governance with GBB. A limited portfolio would be screened for scientific, IP, commercial and compliance fit, with capital released only against agreed milestones. 

The project has three connected elements. First, it provides sponsored preclinical acceleration, including feasibility assessment, AI-assisted optimisation, experimental validation, early developability work and CMC-oriented planning. Second, it activates local capability through live projects, technical workshops, joint reviews, common data and quality workflows, selected training and qualification of suitable research, laboratory or CDMO partners. Third, it creates a portfolio of future partnering opportunities. Programs may remain sponsor-owned or, where justified, be considered for co-development, licensing, option or project-vehicle structures.

For investors, this is an opportunity to support a repeatable platform and managed portfolio rather than one binary therapeutic bet. Capital can support program execution, capability activation, portfolio strategy, partnering, governance and compliance. The anchor-market model protects capital discipline: geographic expansion or deeper local participation should follow only after the pilot demonstrates technical progress, partner quality, demand and investor alignment.

For participating countries, the platform can strengthen the translation of local science into development-relevant biologic assets, expose sponsors and researchers to integrated development workflows, develop specialised talent, and create a stronger foundation for future co-development, licensing and regional collaboration. It does not promise immediate local manufacturing. Instead, it creates a pathway toward deeper ecosystem participation as local partners demonstrate the quality, capability and demand required for more advanced workstreams.

Strong governance is essential. Each collaboration should have a joint steering committee overseeing program selection, milestone release, budgets, partner participation and major scope changes. GBB should retain its pre-existing platform technology and know-how, while project-specific IP, rights, data access, publication and commercialisation responsibilities are defined in definitive agreements. Activities must comply with applicable data-governance, quality, biosafety, biosecurity, export-control, regulatory and IP requirements.

GBB is seeking anchor investors and strategic country partners to co-design the first pilot. Partners would shape the therapeutic focus, program selection, local ecosystem participation, capability plan and, where appropriate, co-development or licensing structure. The platform connects Belt & Road capital, local scientific ambition and GBB’s integrated preclinical capabilities to create stronger biologic-development opportunities and a durable basis for regional life-sciences collaboration.